Background In preclinical studies, davunetide promoted microtubule stability and reduced tau phosphorylation. Because progressive supranuclear palsy (PSP) is linked to tau pathology, davunetide could be a treatment for PSP. We assessed the safety and effi cacy of davunetide in patients with PSP.
Introduction
Progressive supranuclear palsy (PSP) is a neurodegenerative cause of atypical parkinsonism for which there are no approved or eff ective treatments. 1 At autopsy, insoluble aggregates of the microtubule-associated protein tau are found in neurons and glia throughout the brain, most prominently in the brainstem, deep cerebellar nuclei, and basal ganglia, with variable involve ment of neocortical regions. 2, 3 The most common clinical presentation of PSP, termed Richardson's syndrome, has a prevalence of about 6·5 cases per 100 000 individuals, 4 and characteristically involves early and severe gait instability with falls, a greater slowing of vertical than horizontal saccadic eye movements that progresses to a supranuclear restriction of gaze, slowed movement, rigidity of the axial musculature, dysphagia, and pseudobulbar aff ect, along with variable neuropsychiatric abnormalities and dementia.
Genetically, PSP is strongly linked to the H1 tau gene (MAPT) haplotype and other single nucleotide polymorphisms within the MAPT gene. 5 MAPT mutations that lead to inclusion of the alternatively spliced exon 6 that contains one of the four potential microtubule-binding domains can lead to an autosomal dominant familial syndrome similar to PSP. 7 A diagnosis of Richardson's syndrome is highly predictive of underlying PSP or related tau brain pathologies with predominantly four microtubule-binding repeat (4R) tau deposition, 8 and therefore patients with PSP have been suggested to be an ideal population for testing of tau-directed or microtubuledirected treatments for neurodegenerative disease.
neuroprotective eff ects on cell death and microtubule disruption from a variety of toxic insults and in transgenic mice with one or more human MAPT mutations that typically lead to severe autosomal dominant disease, davunetide ameliorates deposition of hyper phosphorylated, insoluble forms of tau and improves performance on behavioural tests such as the Morris water maze. 10 The results of a 12-week phase 2, randomised placebocontrolled clinical trial of davunetide administered intranasally to 144 individuals with amnestic mild cognitive impairment suggested potential treatment benefi ts on attention and working memory. 6 Because executive function defi cits, often involving working memory and attention, are common in PSP, 11 and on the basis of the proposed mechanism of action of davunetide, promoting stabilisation of microtubules and decreased tau pathology, we tested the hypothesis that davunetide would be an eff ective treatment for PSP in a multicentre, randomised, parallel group, double-blind, placebocontrolled trial. The primary objectives in the study were to assess the safety and effi cacy of davunetide in slowing the rate of progression of the clinical features of PSP.
Methods

Participants
In this phase 2/3 trial, we recruited patients from 48 centres in Australia, Canada, France, Germany, the UK, and the USA. Study visits occurred between Sept 30, 2010 , and Nov 1, 2012.
Participants had to meet the following criteria for the most common clinical presentation of PSP, Richardson's syndrome, which were modifi ed from the PSP criteria from the national Neuroprotection and Natural History in Parkinson Plus Syndromes (NNIPPS) study: 12 at least a 12-month history of postural instability or falls during the fi rst 3 years that symptoms were present; reduced downward saccade velocity or supranuclear ophthalmoplegia; and an akinetic-rigid syndrome with prominent axial rigidity. Additionally, at screening, individuals had to be aged 41-85 years; have a mini-mental state examination (MMSE) score of at least 15; live outside a skilled nursing facility or dementia care facility; be able to ambulate independently or to take at least fi ve steps with minimal assistance; have PSP symptoms for less than 5 years or symptoms for more than 5 years with a Progressive Supranuclear Palsy Rating Scale (PSPRS) 13 score of at least 40; and be able to undergo an MRI scan during screening.
Participants were allowed to take levodopa and other medications for Parkinson's disease (except rasagiline) if the dose had been stable for 60 days before screening. They were permitted to take rasagiline or coenzyme Q10 (ubidecarenone) if the dose was stable for at least 90 days before screening.
Exclusion criteria included a clear and robust benefi t from levodopa at the time of screening, evidence of motor neuron disease, use of acetylcholinesterase inhibitors, antipsychotic drugs (other than quetiapine), memantine, lithium carbonate, methylene blue (methylthioninium chloride), or other putative diseasemodifying drugs for PSP (see appendix for a complete list of exclusion criteria).
Ethics approval was obtained at each site from the local ethics committee and all participants gave written informed consent at the recruitment visit as per local regulations.
Randomisation and masking
Participants were randomly assigned in a 1:1 ratio with permutated blocks to davunetide (30 mg, as two 0·1 mL puff s per nostril, twice daily-ie, four puff s per nostril per day, to give eight puff s and 60 mg in total per day) from a multidose, metered nasal spray or matching placebo nasal spray (without davunetide, in identical bottles with similar nasal sensation when administered) for 52 weeks. The dose was the maximum that could be feasibly delivered by this route and corresponded to about twice that known to be eff ective in animal models. 10 All participants and study personnel were masked to treatment assignment. Randomisation was stratifi ed centrally by baseline PSPRS score (<40 or ≥40), coenzyme Q10 use (yes or no), and age (<70 years or ≥70 years) with an interactive web response system that was incorporated into the electronic data capture system, and managed by the contract research organisation that supported data gathering (Research Pharmaceutical Services, Fort Washington, PA, USA).
Procedures
Each participant had eight visits over about 59 weeks of study. After the screening visit, the randomisation or baseline visit occurred within 42 days, and the study medication was fi rst dispensed during this visit. Participants returned at weeks 3, 6, 13, 26, 39, and 52 after the baseline visit. After the week 52 visit, the study medication was stopped, and individuals were contacted by telephone at week 53 to assess adverse events and clinical status. Participants who left the study early but for whom an early termination visit was not possible because of disease progression or other factors were assessed with a telephone questionnaire. Study medication compliance was assessed by comparison of the weights of the dispensed nasal spray bottles versus weights at follow-up visits. Participants were judged to be compliant if the calculated weight diff erences were within 75-125% of the expected weights. The primary effi cacy measures were assessed at baseline and weeks 6, 13, 26, 39, and 52, and safety measures were assessed at all visits. Adverse events were grouped according to the Medical Dictionary for Regulatory Activities system organ class. Serious adverse events were defi ned as those leading to hospital admission or death.
Outcomes
The primary outcomes were the PSPRS 13 100%; 100% is normal-ie, no impairment), which is used to measure the overall disability and is based on interviews of a patient and an informant. Secondary outcomes were the Clinical Global Impression of Change (CGIC) 15 and brain ventricular volume as measured with boundary shift integral analysis of T1-weighted MRI scans. 16 Clinical Global Impression of Disease Severity (CGIds) 17 was an exploratory endpoint. Exploratory neuropsychological outcomes were the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) 18 and three additional neuropsychological assessments of executive function (the colour trails, phonemic fl uency [words beginning with F, A, or S per min], and letter-number sequencing). 10 Mood was assessed with the Geriatric Depression Scale. 19 Safety and tolerability of davunetide were assessed according to treatment-emergent adverse events, electrocardiograms (ECGs), nasal examination, and clinical laboratory measures.
For the MRI substudy, MRI scans were done on 1·5T or 3T scanners and all sites had to meet standards set by the Mayo Clinic's Aging and Dementia Imaging Research laboratory (Rochester, MN, USA). Midbrain and superior cerebellar peduncle volumes were derived by label propagation in SPM (version 5) and treated as exploratory outcomes (appendix).
Subsets of patients participated in other exploratory studies. In the fl uid biomarker study, participants underwent lumbar punctures at baseline and 52 weeks for measurement of CSF amyloid β , tau, phosphorylated tau, and neurofi lament light chain (NfL), and plasma was collected at each study visit for assessment of phosphorylated neurofi lament heavy chain (pNFH), which was done on a small subset of cases at baseline and 52 weeks. 20 In a genotyping substudy, the tau haplotype (H1 vs H2) was assessed in each individual by use of single nucleotide polymorphism markers from a recent PSP genome-wide association study as previously described. 5 In a quantitative ocular motor study, vertical and horizontal saccades were measured using infrared oculography (appendix).
Statistical analysis
The target sample size was 300. This trial was designed to achieve a two-sided α of 0·05 at 90% power if the treatment eff ect was 4·13 PSPRS points (ie, a 37·5% diff erence relative to an expected placebo change from baseline of 11·0, SD 11·0), based on reported natural history data. 13 An intention-to-treat analysis was used for the primary and secondary outcomes that included all participants who received at least one dose of medication and had a postbaseline effi cacy assessment. For the primary analyses, we used a rank-based method to incorporate deaths and loss to follow-up and to allow for skewed data. We assumed patients who were lost to follow-up behaved like those in 21 Participants who discontinued follow-up would be expected to continue worsening with respect to the PSPRS and SEADL if they could be followed up. For participants who discontinued follow-up for reasons other than death, the last observation recorded was used to assign the rank after subtraction of the mean change from that timepoint to the end of the treatment in the placebo group. With these ranks, a stratifi ed rank test was done with the use of a permutation test with strata formed by the randomisation strata as described elsewhere. 22 For the CSF analyses, the 52-week changes from baseline values were compared between treatment groups with a Wilcoxon test. Because no treatment-related diff erences were identifi ed, data were combined for Spearman correlations with clinical and imaging variables.
This trial is registered with Clinicaltrials.gov, number NCT01110720.
Role of the funding source
The study was sponsored by Allon Therapeutics (Vancouver, BC, Canada), which was purchased by Paladin Laboratories in August, 2013. The study was designed by an academic steering committee in collaboration with the sponsor. The sponsor funded data gathering, the planned analyses, and an initial interpretation of the data. All authors had full access to the data, no medical writer or editor was employed, and the decision to submit the manuscript was made by the authors without input from any corporate entity. All authors had fi nal responsibility for the decision to submit the paper for publication. Figure 1 shows that 360 individuals were assessed for eligibility and 313 were randomly assigned to davunetide (n=157) or placebo (n=156). Table 1 shows that the baseline characteristics did not diff er between the davunetide and placebo groups. Medication compliance was similar between the two groups (mean for davunetide group 92·9% [SD 24·9] and for placebo group 95·0% [20·5]).
Results
There were no diff erences between the davunetide and placebo groups in the primary effi cacy endpoints-52-week changes from baseline in the PSPRS and SEADL-in either the primary intention-to-treat analysis (table 2; fi gure 2) or a post-hoc analysis of participants who completed all study visits (table 3) . Likewise, sensitivity analyses to account for number and time of deaths in each group, and eff ects of demographic variables and concomitant medications, did not show any diff erences between treatment groups (data not shown). No diff erences were noted in the treatment and placebo groups in the secondary effi cacy measurements CGIC and change in ventricular volume on MRI scans (table 3) . A treatment eff ect was not shown for the exploratory clinical endpoints RBANS, executive function tests, CGIds, or GDS.
For the exploratory imaging, ocular motor, and plasma and CSF biomarker endpoints, no diff erences were noted in rates of change between treatment groups (table 3). All MRI measurements, including total ventricular, total brain, midbrain, and superior cerebellar peduncle volumes, showed progressive atrophy over 1 year based on the 95% CIs in the combined study population (table 3) . Horizontal saccade latency increased and vertical fi rst saccade gain decreased over 1 year (table 3; no changes were noted in the other measures; data not shown). Of the fi ve fl uid analytes, only the CSF NfL concentrations changed over time (table 3) . In a post-hoc analysis, the 1 year change in NfL levels was correlated with the change in superior cerebellar peduncle volume (Spearman's r=-0·450, p=0·045; fi gure 3) and the oculomotor subscale of the PSPRS (r=0·609; p=0·003; fi gure 3). There was a non-signifi cant correlation between NfL and total PSPRS (r=0·357, p=0·10). No correlations were found between NfL and SEADL or CGIC. Similar numbers of individuals in the davunetide and placebo groups had treatment-emergent adverse events (table 4). 11 deaths occurred in the davunetide group and ten in the placebo group. 54 serious adverse events were reported in each of the treatment groups. All serious adverse events in both groups were judged to be disease related or attributable to disease progression. Most adverse events were mild to moderate and were evenly distributed between treatment groups. More participants in the davunetide group (n=21) than in the placebo group (n=12) had adverse events leading to study drug discontinuation, with most related to epistaxis or nasal congestion. There were no diff erences in the ECG or safety laboratory values between treatment groups (data not shown).
Mean 52 week change (95% CI)
Mean diff erence (95% CI) p value
Davunetide Placebo Total
Clinical outcomes n=118 n=123 n=241
CGIds ‡ 0·9 (0·8 to 1·0) 0·9 (0·7 to 1·0) 0·9 (0·8 to 1·0) 0·03 (-0·19 to 0·25) 0·73
GDS ‡ 0·3 (-0·7 to 1·3) 0·8 (-0·1 to 1·6) 0·6 (-0·1 to 1·2) -0·5 (-1·8 to 0·9) 0·52
Neuropsychological outcomes n=106 n=111 n=217
RBANS (total scaled) ‡ -5·6 (-7·3 to -3·9) -6·4 (-7·9 to -4·9) 6·4 (5·3 to 7·5) 0·7 (-1·7 to 3·1) 0·55 RBANS (total raw) ‡ -20·1 (-24·3 to -15·8) -23·8 (-33·8 to -13·9) -22·0 (-24·8 to -19·3) 3·8 (-2·8 to 10·3) 0·35 Phonemic fl uency (words per min) ‡ -2·0 (-1·2 to -2·8) -2·3 (-3·1 to -1·5) -2·1 (-2·7 to -1·5) 0·3 (-0·6 to 2·0) 0·63
Letter number sequence ‡ -1·0 ( 
Discussion
In this trial, 52 weeks of davunetide treatment had no benefi cial eff ect in patients with PSP. Small diff erences were noted in the frequency of nasal adverse events between the davunetide and the placebo groups. The groups were well matched at baseline, and the primary outcome measures PSPRS and SEADL showed the expected yearly changes in both groups, suggesting that the study was adequately powered to detect a treatment eff ect of davunetide if one had existed. No eff ects of davunetide were noted on the secondary outcome measures CGIC and the yearly rate of brain atrophy. Additionally, no eff ects of davunetide were noted on the rates of change in various exploratory cognitive assessments, volumetric MRI measurements or, in a small subset of individuals, CSF neurodegenerative disease biomarkers. Because pharmacokinetic measurements of davunetide were not done as part of this study, and there are no known pharmacodynamic biomarkers available for davunetide, we cannot be certain that suffi cient concentrations of davunetide entered the CNS to exert an eff ect, we used the correct dose, or the drug engaged its target. However, our results defi nitively show that davunetide, as administered, is not an eff ective treatment for PSP, despite preclinical data suggesting benefi ts related to amelioration of tau pathology. Nonetheless, this study is one of the largest clinical trials done in patients with PSP, and it provides new information about disease progression, longitudinal imaging, and fl uid biomarker changes that should be useful in the design of future studies.
To the best of our knowledge, this study is the fi rst pivotal (intended for registration) clinical trial of a tau-directed therapeutic agent for PSP (panel), the fi rst to report longitudinal CSF biomarker analyses in PSP, and the largest multicentre clinical trial to measure longitudinal brain volume in PSP and use PSPRS. 13 A recent, negative, 1-year, multicentre trial of the glycogen synthase kinase-3 inhibitor tideglusib also used PSPRS and identifi ed a similar rate of decline. 23 Previous, shorter duration, single-centre clinical trials used PSPRS, with one showing a small benefi t of coenzyme Q10 treatment 24 and another showing no eff ect of donepezil on this scale. 25 Importantly, we noted a mean rate of yearly reduction on the PSPRS of 11·1 points (95% CI 9·9-12·3), which is nearly identical to the rate from a single-centre validation study for which only one rater assessed all the individuals. 13 The 93% survival for both groups combined over 53 weeks of follow-up was slightly higher than predicted from the PSPRS validation study (87%) based on the mean baseline PSPRS score of 40 in our patient population, but similar to the survival in the tideglusib trial. 13 For the coprimary endpoint SEADL, the mean yearly rate of reduction was 17% (15) (16) (17) (18) (19) , which is nearly identical to that reported for the NNIPPS clinical trial 12 of riluzole for PSP and the tideglusib trial in patients displaying a similar baseline degree of impairment. 17 Together, these results suggest that the diagnostic criteria for PSP we used are reliable for recruiting patients with mild to moderate PSP into multicentre trials and that, once enrolled, such individuals have a highly predictable rate of clinical decline.
With the caveat that we had few samples to analyse, we noted that the standard 36 total tau, phosphorylated tau, and β amyloid concentrations, which are commonly studied in Alzheimer's disease, did not change over 1 year in patients with PSP. By contrast, CSF NfL concentrations increased over 52 weeks in the participants, and in a post-hoc analysis the longitudinal changes in CSF NfL concentrations were correlated with changes in clinical ocular motor ratings on the PSPRS and changes in superior cerebellar peduncle volume on MRI scans. Of note, CSF NfL concentrations have been shown to be elevated in PSP and correlated with disease severity as measured by Hoehn and Yahr scores, 37 and are correlated with disease severity in other forms of frontotemporal lobar degeneration, but not in Alzheimer's disease. 20 NfL concentrations decrease in response to disease-modifying treatment in multiple sclerosis. 38 Our fi ndings suggest that CSF NfL is likely to be a useful biomarker of disease progression in PSP. Although we noted no longitudinal changes in CSF tau or phosphorylated tau, both measurements have identifi ed eff ects of anti-amyloid treatments in clinical trials in patients with Alzheimer's disease where no longitudinal increase in levels was identifi ed in the placebo group, 39 similar to natural history studies showing no change in CSF tau. 40 Thus, it remains possible that these measurements might be useful in future PSP trials, particularly those of tau-directed agents.
This is the largest multicentre study to measure longitudinal brain volume changes in PSP. We noted no treatment-related diff erence in brain atrophy rates, with a mean yearly brain atrophy similar to the 1% reported previously in single-centre natural history studies. 16, 41, 42 The tideglusib trial 23 included a smaller MRI substudy (n=37) that showed reduced whole brain and parietaloccipital atrophy rates in treated individuals. 35 Of note, the mean yearly brain atrophy in the placebo group of the tideglusib study was 3·1%, which is higher than what we noted (0·86%). Because we used volumetric methods that were similar to previous PSP MRI natural history studies and obtained similar results, the diff erences in brain atrophy rates between our study and the tideglusib MRI substudy might have arisen from the diff erent methods for volumetric analysis or diff erences in clinical characteristics between the MRI study populations. Although our mean yearly ventricular volume expansion of 9·4% per year was similar to previous studies, midbrain atrophy rates have been more variable, and the rate of 3·5% in our study fell in the lower range of previously reported values (2·2-10·5%). 16, 41, 42 In our study, the 7·3% atrophy per year in the superior cerebellar peduncle was higher than the 3·5% rate reported in a previous study. 41 The subtle diff erences in regional atrophy rates are likely to have arisen from the diff erent methods for volumetric imaging used here.
The results of our study show the feasibility of doing multicentre clinical trials in patients with PSP, and the reproducibility of rates of change on standard outcome measures such as the PSPRS. They also show the potential utility of volumetric brain imaging and CSF NfL as biomarkers of disease progression in PSP. Similar to the recent clinical trial of tideglusib in PSP, 35 no clinical benefi ts were noted. Although a treatment eff ect on brain atrophy rate was identifi ed in the tideglusib trial, the relevance of this fi nding is unclear because there were no associated clinical benefi ts. Importantly, neither the tideglusib trial nor our study included pharmacodynamic measurements that might have shown that the investigational agent engaged its molecular target in the participants and had the predicted mechanistic eff ect. Therefore, the biological hypotheses in both of these trials were not adequately tested. Future studies of tau-directed treatments should be pursued in PSP, but must incorporate phamacodynamic measures of target engagement. Tau PET imaging 43 is a promising new biomarker that might help to show target Data are number (%), unless otherwise indicated. *Adverse events leading to discontinuation of study medication in more than two individuals. †Safety laboratory or other safety measures. Table 4 : Adverse events in more than 5% of study participants engagement and allow identifi cation of patients with PSP at earlier stages of disease, when tau-directed treatments are most likely to be eff ective.
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